Literature DB >> 26453015

Effects of a ketogenic diet on auditory gating in DBA/2 mice: A proof-of-concept study.

Jason R Tregellas1, Jason Smucny2, Kristina T Legget2, Karen E Stevens3.   

Abstract

Although the ketogenic diet has shown promise in a pilot study and case report in schizophrenia, its effects in animal models of hypothesized disease mechanisms are unknown. This study examined effects of treatment with the ketogenic diet on hippocampal P20/N40 gating in DBA/2 mice, a translational endophenotype that mirrors inhibitory deficits in P50 sensory gating in schizophrenia patients. As expected, the diet increased blood ketone levels. Animals with the highest ketone levels showed the lowest P20/N40 gating ratios. These preliminary results suggest that the ketogenic diet may effectively target sensory gating deficits and is a promising area for additional research in schizophrenia. Published by Elsevier B.V.

Entities:  

Keywords:  Gating; Hippocampus; Ketogenic diet; P50; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26453015      PMCID: PMC4827327          DOI: 10.1016/j.schres.2015.09.022

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  44 in total

1.  A PILOT STUDY OF THE KETOGENIC DIET IN SCHIZOPHRENIA.

Authors:  A PACHECO; W S EASTERLING; M W PRYER
Journal:  Am J Psychiatry       Date:  1965-05       Impact factor: 18.112

Review 2.  INPUT DYSFUNCTION IN SCHIZOPHRENIA.

Authors:  P H VENABLES
Journal:  Prog Exp Pers Res       Date:  1964

3.  Disorders of attention and perception in early schizophrenia.

Authors:  A MCGHIE; J CHAPMAN
Journal:  Br J Med Psychol       Date:  1961

4.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Authors:  Ann Olincy; Josette G Harris; Lynn L Johnson; Vicki Pender; Susan Kongs; Diana Allensworth; Jamey Ellis; Gary O Zerbe; Sherry Leonard; Karen E Stevens; James O Stevens; Laura Martin; Lawrence E Adler; Ferenc Soti; William R Kem; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2006-06

5.  Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha 7 nicotinic acetylcholine receptors.

Authors:  Kenji Hashimoto; Masaomi Iyo; Robert Freedman; Karen E Stevens
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

6.  Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity.

Authors:  Vicente Molina; Javier Sanz; Fernando Sarramea; Carlos Benito; Tomás Palomo
Journal:  J Psychiatr Res       Date:  2005-03       Impact factor: 4.791

7.  The left medial temporal region and schizophrenia. A PET study.

Authors:  K J Friston; P F Liddle; C D Frith; S R Hirsch; R S Frackowiak
Journal:  Brain       Date:  1992-04       Impact factor: 13.501

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

9.  Neuronal substrates of sensory gating within the human brain.

Authors:  Thomas Grunwald; Nashaat N Boutros; Nico Pezer; Joachim von Oertzen; Guillen Fernández; Carlo Schaller; Christian E Elger
Journal:  Biol Psychiatry       Date:  2003-03-15       Impact factor: 13.382

10.  Patterns of cerebral blood flow in schizophrenia.

Authors:  P F Liddle; K J Friston; C D Frith; S R Hirsch; T Jones; R S Frackowiak
Journal:  Br J Psychiatry       Date:  1992-02       Impact factor: 9.319

View more
  2 in total

1.  Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?

Authors:  Jamie Joseph; Colin Depp; Pei-An B Shih; Kristen S Cadenhead; Geert Schmid-Schönbein
Journal:  Front Neurosci       Date:  2017-03-27       Impact factor: 4.677

2.  Ketogenic Therapy in Serious Mental Illness: Emerging Evidence.

Authors:  Zoltán Sarnyai; Christopher M Palmer
Journal:  Int J Neuropsychopharmacol       Date:  2020-07-29       Impact factor: 5.176

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.